Wednesday, July 22

Browsing: H4K12

Research

AARS1-catalyzed H4K12 lactylation promotes HCC resistance to targeted therapy by activating RAPGEF3-RAP1 signaling

By NewsCancerJuly 22, 20260

Although receptor tyrosine kinase inhibitors (sorafenib and lenvatinib) have been applied as a first-line targeted therapy for advanced unresectable hepatocellular…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City

Optimal Sequencing of Bispecific Antibodies and CAR T Cells Remains Unclear

Pelareorep Earns FDA Fast Track Designation in Second-Line Anal Cancer

Browsing: H4K12

AARS1-catalyzed H4K12 lactylation promotes HCC resistance to targeted therapy by activating RAPGEF3-RAP1 signaling

Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City

Optimal Sequencing of Bispecific Antibodies and CAR T Cells Remains Unclear

Pelareorep Earns FDA Fast Track Designation in Second-Line Anal Cancer

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City

Optimal Sequencing of Bispecific Antibodies and CAR T Cells Remains Unclear

Pelareorep Earns FDA Fast Track Designation in Second-Line Anal Cancer

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Latest Post

Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City

Optimal Sequencing of Bispecific Antibodies and CAR T Cells Remains Unclear

Pelareorep Earns FDA Fast Track Designation in Second-Line Anal Cancer

Subscribe to Updates

What's Hot

Browsing: H4K12